Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Savolitinib in NSCLC: progress in the MET exon 14 journey535
Broad protection from SARS-CoV-2 variants without antigen matching330
European Respiratory Society International Congress 2022268
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress264
Opioids bring peace to patients with IPF cough248
Impact of Myanmar's earthquake on respiratory health245
Predatory publishers appear in PubMed (and your inbox)240
FLiRTing with danger as SARS-CoV-2 variants evolve232
Thoracentesis: an old story and some new sources217
Chronic obstructive pulmonary disease: 10 years of precision-guided success214
Correction to Lancet Respir Med 2024; 12: 129–40208
Interstitial lung disease: a decade of progress and hope202
The burden of tuberculosis in Libya201
Concerns about PRISm201
Long COVID: systemic inflammation and obesity as therapeutic targets198
Rituximab for connective tissue disease-associated interstitial lung disease198
Major gaps in childhood pneumonia research priorities remain190
Rethinking the role of procalcitonin in suspected sepsis190
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership188
US Senate committee investigates asthma inhaler prices187
Australia bans engineered stone to prevent silicosis178
Video laryngoscopy is not the nemesis of direct laryngoscopy177
Predicted bodyweight—a misleading metric for tidal volume titration?174
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis168
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study167
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop162
Concerns regarding a suggested long COVID paradigm – Authors' reply159
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros158
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial154
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials149
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis148
Chronic respiratory diseases in Asia: time for action147
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials138
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts137
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial136
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis134
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply132
Claudio Castanos—leader in cystic fibrosis care in Argentina131
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges128
Solid and semi-solid perspectives in thoracic surgery127
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta126
Genetic associations and lung function in IPF: unexpected answers, persistent questions123
Extracorporeal cardiopulmonary resuscitation: not why, but how122
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub119
Trump administration decimates worker health oversight118
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m115
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial115
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials115
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO114
Sphaerosymphony: turning air quality data into music110
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial110
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study110
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial109
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s109
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis109
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis108
Correction to Lancet Respir Med 2022; 10: 972–84107
Correction to Lancet Respir Med 2021; 9: 1275–87105
Correction to Lancet Respir Med 2025; 13: 244–55102
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co101
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts101
Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis101
Association of SARS-CoV-2 infection and persistence with long COVID100
Chronic cough as a disease: implications for practice, research, and health care99
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study98
Health effects from climate-driven events: lessons learnt97
Choice overload for RSV prevention—how to form your opinion96
Spirometry in female individuals – Authors' reply96
The Ramp to Nowhere: When hope slips through the cracks in care95
Developments and priorities in bronchiectasis research95
US lung cancer report suggests years of encouraging progress under threat from health agency cuts94
Realignment of clinical research after the COVID-19 era92
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration92
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing92
Tackling tuberculosis: what lies beneath the surface?90
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma89
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO88
COP27 Climate Change Conference: urgent action needed for Africa and the world87
Underappreciated causes of obstructive lung disease84
Liberal or restrictive transfusion for VV ECMO84
0.1048538684845